Literature DB >> 3493097

Pyrogenic and haematological effects of the interferon-inducing 22K factor (interleukin 1 beta) from human leukocytes.

J van Damme, G Opdenakker, M de Ley, H Heremans, A Billiau.   

Abstract

Human 22K factor is a cytokine released by mitogen-stimulated peripheral blood leukocytes. The factor stimulates fibroblasts to produce interferon-beta (IFN-beta) and thereby exerts antiviral activity on these cells. It was identified as interleukin-1 beta (IL-1 beta) by its amino-acid sequence and spectrum of biological activities. The pyrogenic and haematological effects of pure 22K factor were studied at different doses and were compared with those of endotoxin and interferon. 22K factor dose-dependently induced fever in rabbits, 0.1 microgram/kg being a minimum effective dose. Intravenous injection in rabbits caused immediate granulocytosis at low dose, while a profound granulopenia followed by hypergranulocytosis was observed at high dose. Preparations of pure 22K factor were free of detectable lipopolysaccharide and lost their biological effects after heat-treatment. Repeated injections of 22K factor did not result in a state of tolerance. There is no evidence that the effects in vivo of 22K factor were mediated by induction of interferon. Human 22K factor, a weak and species-specific inducer in IFN-beta in vitro, did not induce detectable amounts of circulating interferon in rabbits. Moreover, injection of rabbits with IFN-beta resulted in a weak effect on body temperature and granulocyte counts as compared to similar doses of 22K factor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3493097      PMCID: PMC1542544     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Possible involvement of leukocytic endogenous mediator in granulopoiesis.

Authors:  R F Kampschmidt; H F Upchurch
Journal:  Proc Soc Exp Biol Med       Date:  1977-05

Review 2.  Interleukin 1: an immunological perspective.

Authors:  S K Durum; J A Schmidt; J J Oppenheim
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

3.  Mass production of human interferon in diploid cells stimulated by poly-I:C.

Authors:  A Billiau; M Joniau; P De Somer
Journal:  J Gen Virol       Date:  1973-04       Impact factor: 3.891

4.  Granulocytic hyperplasia and induction of tolerance in response to chronic endotoxin administration.

Authors:  P A Chervenick; D R Boggs
Journal:  J Reticuloendothel Soc       Date:  1971-03

5.  Neutrophil release after injections of endotoxin or leukocytic endogenous mediator into rats.

Authors:  R F Kampschmidt; H F Upchurch
Journal:  J Reticuloendothel Soc       Date:  1980-08

6.  Purification of human interleukin 1 from human monocyte culture supernatants and identity of thymocyte comitogenic factor, fibroblast-proliferation factor, acute-phase protein-inducing factor, and endogenous pyrogen.

Authors:  K Matsushima; S K Durum; E S Kimball; J J Oppenheim
Journal:  Cell Immunol       Date:  1985-05       Impact factor: 4.868

7.  Purification of human fibroblast interferon by zinc chelate chromatography.

Authors:  J W Heine; J Van Damme; M de Ley; A Billiau; P de Somer
Journal:  J Gen Virol       Date:  1981-05       Impact factor: 3.891

8.  Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines.

Authors:  M P Bevilacqua; J S Pober; M E Wheeler; R S Cotran; M A Gimbrone
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

9.  Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1.

Authors:  J Van Damme; M De Ley; G Opdenakker; A Billiau; P De Somer; J Van Beeumen
Journal:  Nature       Date:  1985 Mar 21-27       Impact factor: 49.962

10.  Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans.

Authors:  A Billiau; P De Somers; V G Edy; E De Clercq; H Heremans
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

View more
  8 in total

Review 1.  Interaction of interferon with other cytokines.

Authors:  G Opdenakker; Y Cabeza-Arvelaiz; J Van Damme
Journal:  Experientia       Date:  1989-06-15

2.  Endotoxin-induced cytokine gene expression in vivo. II. Regulation of tumor necrosis factor and interleukin-1 alpha/beta expression and suppression.

Authors:  T R Ulich; K Z Guo; B Irwin; D G Remick; G N Davatelis
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

3.  The interleukin-1β/CXCL1/2/neutrophil axis mediates host protection against group B streptococcal infection.

Authors:  C Biondo; G Mancuso; A Midiri; G Signorino; M Domina; V Lanza Cariccio; N Mohammadi; M Venza; I Venza; G Teti; C Beninati
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

Review 4.  The biological activities of interleukin-1.

Authors:  W E Fibbe; M R Schaafsma; J H Falkenburg; R Willemze
Journal:  Blut       Date:  1989-08

5.  Effects of chlorpromazine on PMN-mediated activities in vivo and in vitro.

Authors:  R Bertini; J M Wang; M Mengozzi; J Willems; M Joniau; J Van Damme; P Ghezzi
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

6.  A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity.

Authors:  J Van Damme; J Van Beeumen; G Opdenakker; A Billiau
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

7.  Essential role of interleukin-1 signaling in host defenses against group B streptococcus.

Authors:  Carmelo Biondo; Giuseppe Mancuso; Angelina Midiri; Giacomo Signorino; Maria Domina; Veronica Lanza Cariccio; Mario Venza; Isabella Venza; Giuseppe Teti; Concetta Beninati
Journal:  mBio       Date:  2014-09-09       Impact factor: 7.867

8.  Biological Characterization of Commercial Recombinantly Expressed Immunomodulating Proteins Contaminated with Bacterial Products in the Year 2020: The SAA3 Case.

Authors:  Sara Abouelasrar Salama; Mirre De Bondt; Nele Berghmans; Mieke Gouwy; Vivian Louise Soares de Oliveira; Sergio C Oliveira; Flavio A Amaral; Paul Proost; Jo Van Damme; Sofie Struyf; Mieke De Buck
Journal:  Mediators Inflamm       Date:  2020-07-06       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.